You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFumagillin
Accession NumberDB02640  (EXPT01509)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FlisintSanofi
FugillinUpjohn
FurnidilAbbott
Brand mixturesNot Available
SaltsNot Available
Categories
UNII7OW73204U1
CAS number23110-15-8
WeightAverage: 460.5598
Monoisotopic: 460.246103506
Chemical FormulaC26H36O7
InChI KeyXXVWUXWNPOXVQB-GJNCDYHDSA-N
InChI
InChI=1S/C26H36O7/c1-18(2)14-15-20-26(4,33-20)24-23(31-5)19(16-17-25(24,3)30)32-22(29)13-11-9-7-6-8-10-12-21(27)28/h6-14,19-20,23-24,30H,15-17H2,1-5H3,(H,27,28)/b8-6+,9-7+,12-10+,13-11+/t19-,20+,23+,24?,25-,26-/m0/s1
IUPAC Name
(2E,4E,6E,8E)-10-{[(1S,2S,4S)-4-hydroxy-2-methoxy-4-methyl-3-[(2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]cyclohexyl]oxy}-10-oxodeca-2,4,6,8-tetraenoic acid
SMILES
CO[C@@H]1[[email protected]](CC[C@@](O)(C)C1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Methionine aminopeptidase 2Proteinunknown
ligand
HumanP50579 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Fumagillin.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Fumagillin.Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Fumagillin.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Fumagillin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fumagillin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Fumagillin.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Fumagillin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Fumagillin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Fumagillin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fumagillin.Approved, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Fumagillin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fumagillin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Fumagillin.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Fumagillin.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Peterson, M.H., Goldstein, A.W. and Denison, F.W. Jr.; U.S. Patent 2,803,586; August 20, 1957; assigned to Abbott Laboratories.

General ReferencesNot Available
External Links
ATC CodesP01AX10
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.907
Blood Brain Barrier-0.5281
Caco-2 permeable-0.578
P-glycoprotein substrateSubstrate0.7621
P-glycoprotein inhibitor IInhibitor0.5957
P-glycoprotein inhibitor IIInhibitor0.8966
Renal organic cation transporterNon-inhibitor0.9216
CYP450 2C9 substrateNon-substrate0.8485
CYP450 2D6 substrateNon-substrate0.8869
CYP450 3A4 substrateSubstrate0.639
CYP450 1A2 substrateNon-inhibitor0.8839
CYP450 2C9 inhibitorNon-inhibitor0.7431
CYP450 2D6 inhibitorNon-inhibitor0.9299
CYP450 2C19 inhibitorNon-inhibitor0.7701
CYP450 3A4 inhibitorNon-inhibitor0.7188
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9386
Ames testAMES toxic0.6248
CarcinogenicityNon-carcinogens0.9203
BiodegradationNot ready biodegradable0.8205
Rat acute toxicity2.7268 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9914
hERG inhibition (predictor II)Non-inhibitor0.9147
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point190-192Peterson, M.H., Goldstein, A.W. and Denison, F.W. Jr.; U.S. Patent 2,803,586; August 20, 1957; assigned to Abbott Laboratories.
Predicted Properties
PropertyValueSource
Water Solubility0.00673 mg/mLALOGPS
logP4.45ALOGPS
logP3.93ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)4.88ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area105.59 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity130.34 m3·mol-1ChemAxon
Polarizability51.18 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as medium-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 4 and 12 carbon atoms.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassFatty acids and conjugates
Direct ParentMedium-chain fatty acids
Alternative Parents
Substituents
  • Medium-chain fatty acid
  • Heterocyclic fatty acid
  • Fatty acid ester
  • Epoxy fatty acid
  • Cyclohexanol
  • Branched fatty acid
  • Unsaturated fatty acid
  • Dicarboxylic acid or derivatives
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Tertiary alcohol
  • Cyclic alcohol
  • Carboxylic acid ester
  • Oxacycle
  • Organoheterocyclic compound
  • Ether
  • Oxirane
  • Dialkyl ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
ligand
General Function:
Poly(a) rna binding
Specific Function:
Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). The catalytic activity of human METAP2 toward Met-Val peptides is consistently two orders of magnitude higher than that of METAP1, suggesting that it is responsibl...
Gene Name:
METAP2
Uniprot ID:
P50579
Molecular Weight:
52891.145 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23